PUBLIC COMPANY
saveGamida Cell Ltd
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
- phase3Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
- phase2Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
- —Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
🐶 Hiring Signal
News
- Karyopharm, deep in debt, to sell itself in bankruptcyThe parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.biopharma_dive · 14d ago
- Karyopharm files Chapter 11, lines up Ayrmid as lead bidder in planned mergerIn an answer to Karyopharm's cash crisis, Irish biotech Ayrmid has agreed to make the first bid on the struggling biopharma's assets in a court supervised auction, teeing up a potential hematology…fiercebiotech · 15d ago
comments(0)
5-min edit window · permanent after that